Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol.
about
Anion Gap Toxicity in Alloxan Induced Type 2 Diabetic Rats Treated with Antidiabetic Noncytotoxic Bioactive Compounds of Ethanolic Extract of Moringa oleiferaEffects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover studyLiraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes.
P2860
Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Adding liraglutide to the back ...... sed controlled study protocol.
@en
Adding liraglutide to the back ...... ewly diagnosed type-2 diabetes
@nl
type
label
Adding liraglutide to the back ...... sed controlled study protocol.
@en
Adding liraglutide to the back ...... ewly diagnosed type-2 diabetes
@nl
prefLabel
Adding liraglutide to the back ...... sed controlled study protocol.
@en
Adding liraglutide to the back ...... ewly diagnosed type-2 diabetes
@nl
P2093
P2860
P50
P1433
P1476
Adding liraglutide to the back ...... ised controlled study protocol
@en
P2093
AddHope2 Trial Study Group
Christian Anholm
Malene S Klit
Ole P Kristiansen
P2860
P304
P356
10.1136/BMJOPEN-2014-005942
P50
P577
2014-07-16T00:00:00Z